5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | NEUTRAL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.79▼ | 4.75▲ | 4.74▲ | 4.76▲ | 4.95▼ |
MA10 | 4.76▲ | 4.75▲ | 4.73▲ | 4.73▲ | 4.72▲ |
MA20 | 4.75▲ | 4.72▲ | 4.72▲ | 4.98▼ | 4.87▼ |
MA50 | 4.71▲ | 4.77▲ | 4.75▲ | 4.75▲ | 4.13▲ |
MA100 | 4.77▲ | 4.75▲ | 4.88▼ | 4.86▼ | 6.06▼ |
MA200 | 4.76▲ | 4.96▼ | 4.81▼ | 4.49▲ | 29.68▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.010▲ | 0.010▲ | -0.035▼ | -0.010▼ |
RSI | 57.074▲ | 55.567▲ | 53.878▲ | 49.337▼ | 51.555▲ |
STOCH | 79.026 | 59.874 | 62.178 | 43.890 | 50.543 |
WILL %R | -36.667 | -34.375 | -25.000▲ | -61.881 | -52.186 |
CCI | 72.492 | 171.354▲ | 188.471▲ | -33.722 | -9.401 |
Friday, April 26, 2024 03:40 AM
Real-time Data is provided using Nasdaq Last Sale Data Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology ...
|
Thursday, April 25, 2024 12:04 PM
Vistagen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies f ...
|
Thursday, April 25, 2024 11:17 AM
Vistagen (VTGN) reported positive results from a Phase 2a study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue. Read more here.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 4.745 | 4.85 | 4.69 | 4.785 | 139,179 |
25/04/24 | 4.69 | 4.77 | 4.55 | 4.70 | 193,293 |
24/04/24 | 4.85 | 4.86 | 4.65 | 4.72 | 147,518 |
23/04/24 | 4.85 | 5.00 | 4.80 | 4.83 | 189,215 |
22/04/24 | 4.83 | 4.8694 | 4.735 | 4.78 | 138,344 |
19/04/24 | 4.68 | 4.78 | 4.66 | 4.76 | 152,105 |
18/04/24 | 4.72 | 4.82 | 4.60 | 4.70 | 193,365 |
17/04/24 | 4.71 | 4.80 | 4.66 | 4.67 | 114,021 |
16/04/24 | 4.64 | 4.81 | 4.40 | 4.65 | 180,007 |
15/04/24 | 4.95 | 4.95 | 4.62 | 4.75 | 274,414 |
|
|
||||
|
|
||||
|
|